XIII Annual INFOTEHNA Pharmaceutical Conference

25 - 27 May 2011, Wörthersee/Klagenfurt, Austria.
INFOTEHNA Group, leading provider of Software Solutions for Pharmaceutical Industry, is organizing its traditional (XIII) Annual Pharmaceutical Conference. Event will take place at idyllic alpine lake Woerthersee in southern Austria.

INFOTEHNA's consultants with guest speakers from Agencies and successful pharmaceutical companies will focus on areas of Regulatory Affairs, Research & Development, Quality Assurance and Quality Control.

Pre-conference day - May 25
Pre-conference day will be devided in two workshops: to newcomers INFOTEHNA's software solutions for faster, easier and efficient work with documentation will be presented, along with several case studies. To loyal customers, INFOTEHNA will unveil new functions of our system, some tricks of Submission Management and show demonstration of Training Management Tool. Event organisers will discuss Pharmacovigilance Documentation in electronic system, connection with Regulatory Authorities and much more.

Conference day - May 26
Speakers from successful Pharma companies and Regulatory Agencies will share their experiences and knowledge in 2 Streams:

1) Regulatory Affairs and Pharmacovigilance
2) Quality and Development

In Hands-on corner you will be able to work with INFOTEHNA's system and test its functionalities, consult experts and get answers to any questions concerning the use of INFOTEHNA's solutions.

For further information and registration, please visit:
http://www.infotehna.com/event/373

About INFOTEHNA
INFOTEHNA Group is with more than 20 years in the industry well established provider of hi-end Enterprise Content Management Software, delivering totally integrated solutions for mission-critical business processes in pharmaceutical industry. They are ready to validate and deploy without expensive customization, and designed with compliance regulations and best practices in mind.

INFOTEHNA Expert Series solutions have over 5000 users in more than 20 countries. With offices in Germany, USA, India, Turkey, Slovenia and Croatia, INFOTEHNA is globally present and highly experienced partner of world's largest Life Science companies.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...